Tarsus Pharmaceuticals, Inc. (TARS)

NASDAQ: TARS · Real-Time Price · USD

82.76

+8.71 (11.76%)

At close: Sep 2, 2026, 4:00 PM EDT

82.39

-0.37 (-0.45%)

Pre-market: Sep 3, 2026, 7:14 AM EDT

Tarsus Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	606.33	451.36	182.95	17.45	25.82	57.03
Revenue Growth	105.17%	146.71%	948.62%	-32.42%	-54.73%	-
Cost of Revenue	105.07	95.01	66.21	51.91	43.58	43.79
Gross Profit	501.26	356.35	116.74	-34.46	-17.76	13.24
Selling, General & Admin	526.44	427.32	237.31	108.7	44.95	25.4
Research & Development	23.36	-	-	-	-	-
Operating Expenses	549.8	427.32	237.31	108.7	44.95	25.4
Operating Income	-48.54	-70.97	-120.57	-143.16	-62.71	-12.16
Interest Expense	-8.77	-8.94	-7.85	-3.35	-2.2	-
Interest & Investment Income	15.48	15.75	15.01	10.34	3.5	0.04
Other Non Operating Income (Expenses)	-0.34	-0.2	0.39	0.02	0.09	-0
EBT Excluding Unusual Items	-42.16	-64.36	-113.02	-136.15	-61.33	-12.12
Gain (Loss) on Sale of Investments	2.81	-	-0.59	0.26	-0.77	-1.58
Gain (Loss) on Sale of Assets	-	-	-	-	-	-0.07
Other Unusual Items	-	-	-1.94	-	-	-
Pretax Income	-39.35	-64.36	-115.55	-135.89	-62.1	-13.77
Income Tax Expense	7.13	2.06	-	-	-0	0.06
Net Income	-46.48	-66.42	-115.55	-135.89	-62.09	-13.83
Net Income to Common	-46.48	-66.42	-115.55	-135.89	-62.09	-13.83
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	43	42	38	29	25	21
Shares Outstanding (Diluted)	43	42	38	29	25	21
Shares Change	7.95%	11.11%	27.98%	19.35%	19.78%	231.12%
EPS (Basic)	-1.08	-1.59	-3.07	-4.62	-2.52	-0.67
EPS (Diluted)	-1.08	-1.59	-3.07	-4.62	-2.52	-0.67
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	56	-22.31	-84.59	-119	-49.54	3.16
Free Cash Flow Per Share	1.30	-0.53	-2.25	-4.05	-2.01	0.15
Gross Margin	82.67%	78.95%	63.81%	-197.50%	-68.81%	23.22%
Operating Margin	-8.00%	-15.72%	-65.90%	-820.53%	-242.92%	-21.32%
Profit Margin	-7.66%	-14.71%	-63.16%	-778.89%	-240.51%	-24.25%
Free Cash Flow Margin	9.24%	-4.94%	-46.24%	-682.04%	-191.88%	5.54%
EBITDA	-46.2	-69.15	-119.34	-142.28	-62.39	-11.85
EBITDA Margin	-7.62%	-15.32%	-65.23%	-	-241.66%	-20.77%
D&A For EBITDA	2.34	1.82	1.23	0.88	0.33	0.31
EBIT	-48.54	-70.97	-120.57	-143.16	-62.71	-12.16
EBIT Margin	-8.00%	-15.72%	-65.90%	-	-242.92%	-21.32%
Revenue as Reported	606.33	451.36	182.95	17.45	25.82	57.03

SEC Filings: 10-K · 10-Q